[Acute promyelocytic leukaemia]
Tøstesen, M; Østergård, LSG; Kjeldsen, E; Stentoft, J; Nørgaard, JM
| HERO ID | 4241885 |
|---|---|
| In Press | No |
| Year | 2018 |
| Title | [Acute promyelocytic leukaemia] |
| Authors | Tøstesen, M; Østergård, LSG; Kjeldsen, E; Stentoft, J; Nørgaard, JM |
| Journal | Ugeskrift for Laeger |
| Volume | 180 |
| Issue | 3 |
| Abstract | Acute promyelocytic leukaemia has changed from being a highly fatal to a highly curable disease. Over time, key discoveries have identified the genetic and molecular abnormalities, which cause the disease. First choice of treatment has now changed from all-trans retinoic acid (ATRA) and chemotherapy to a chemo-free combination of arsenic trixoide and ATRA. This new regimen has shown equal responses and overall cure rates compared with the previous standard of care containing conventional chemotherapy, but with much lower toxicity. This will pave the way for better and easier treatment for elderly and frail patients. |
| Pmid | 29336301 |
| Is Certified Translation | No |
| Dupe Override | No |
| Is Public | Yes |
| Language Text | Danish |